NCT01027169View on ClinicalTrials.gov

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

October 31, 2009

Conditions
Hepatic Impairment
Interventions
DRUG

safinamide

single dose of 50mg safinamide on Day 1

DRUG

safinamide

single dose of 50mg safinamide on Day 1

DRUG

safinamide

single dose of 50mg safinamide on Day 1

Trial Locations (1)

Unknown

CRS Clinical Research Services Kiel GmbH, Kiel

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT01027169 - A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics | Biotech Hunter | Biotech Hunter